$78.14 2.4%
DXCM Stock Price vs. AI Score
Data gathered: December 23

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Dexcom (DXCM)

Analysis generated October 7, 2024. Powered by Chat GPT.

Dexcom, Inc. is a market leader in continuous glucose monitoring (CGM) systems for diabetes management. Founded in 1999 and headquartered in San Diego, California, Dexcom has focused on developing and marketing CGM devices for people with diabetes. The company's flagship product, the Dexcom G6, allows users to monitor their glucose levels in real time without the need for fingersticks. As a company that operates in the healthcare and medical technology sector, Dexcom is well-positioned to benefit from the increasing prevalence of diabetes worldwide and the shift towards more advanced, patient-friendly monitoring solutions.

Read full AI stock Analysis

Stock Alerts - Dexcom (DXCM)

company logo Dexcom | December 20
Price is up by 5.3% in the last 24h.
company logo Dexcom | December 18
Insider Alert: Stern Sadie is selling shares
company logo Dexcom | November 25
Price is up by 6% in the last 24h.
company logo Dexcom | November 23
Insider Alert: Stern Sadie is selling shares

About Dexcom

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.


Dexcom
Price $78.14
Target Price Sign up
Volume 153,370
Market Cap $31.3B
Year Range $64 - $138.01
Dividend Yield 0%
PE Ratio 48.51
Analyst Rating 83% buy
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '24994M707M594M135M152M0.450
Q2 '241B710M627M144M210M0.430
Q1 '24916M678M562M146M190M0.320
Q4 '231.03B696M657M256M261M0.500
Q3 '23970M638M623M121M247M0.500

Insider Transactions View All

Leach Jacob Steven filed to sell 264,171 shares at $76.9.
December 17 '24
Sylvain Jereme M filed to sell 80,030 shares at $76.9.
December 17 '24
Stern Sadie filed to sell 70,768 shares at $76.9.
December 17 '24
Heller Bridgette P filed to sell 23,349 shares at $76.9.
December 17 '24
Stern Sadie filed to sell 71,192 shares at $74.7.
November 22 '24

What is the Market Cap of Dexcom?

The Market Cap of Dexcom is $31.3B.

What is Dexcom's PE Ratio?

As of today, Dexcom's PE (Price to Earnings) ratio is 48.51.

What is the current stock price of Dexcom?

Currently, the price of one share of Dexcom stock is $78.14.

How can I analyze the DXCM stock price chart for investment decisions?

The DXCM stock price chart above provides a comprehensive visual representation of Dexcom's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dexcom shares. Our platform offers an up-to-date DXCM stock price chart, along with technical data analysis and alternative data insights.

Does DXCM offer dividends to its shareholders?

As of our latest update, Dexcom (DXCM) does not offer dividends to its shareholders. Investors interested in Dexcom should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Dexcom?

Some of the similar stocks of Dexcom are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.